Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Prognostic variables associated with the development of cytokine release syndrome after bispecific antibodies in non-Hodgkin lymphoma patients – the geltamo (Spanish Lymphoma Group) experience

View Full Paper
Ask AI
Bookmark
Share

Authors

ÁSÁngel SernaLMLaura MagnanoPVPedro José Paúl Vidaller

Discussion

Loading...

Member takes

Overview

Multicenter analysis showed cytokine release syndrome risk in non-Hodgkin lymphoma patients treated with bispecific antibodies, suggesting a prognostic model for decision-making.

Key Points

  • To analyze factors associated with cytokine release syndrome in patients with B-cell non-Hodgkin lymphoma receiving bispecific antibodies.
  • Retrospective multicenter analysis of patients treated in the GELTAMO network
  • Grading of cytokine release syndrome followed ASTCT criteria
  • Logistic regression models identified factors associated with CRS
  • 46% of patients developed cytokine release syndrome after treatment
  • Key factors for predicting CRS included IPI/FLIPI score and absolute lymphocyte count
  • Model performance demonstrated AUC of 0.679 for any grade and 0.7132 for grade ≥2 CRS

Cite This Study

Serna et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236deeahttps://doi.org/10.1182/blood-2025-3737
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Risk factors for CRS and NT with bispecific antibodies: Data from the American bispecifics and CART (ABC) consortium2025
  2. 2CRS-RS.5p predictive model informs risk stratification and cytokine release syndrome management following glofitamab treatment in patients with relapsed or refractory diffuse large B-cell lymphoma2025
  3. 3Risk factors for cytokine release syndrome and neurotoxicity in patients receiving epcoritamab or glofitamab for large B cell lymphoma: A multi-center, retrospective, real world analysis.2025 · 1 citations
  4. 4Decreased renal function predicts severe cytokine release syndrome after <scp>CAR</scp> ‐T‐cell therapy for large B‐cell lymphoma2026 · 2 citations
  5. 5Risk factors for CRS and ICANS with Bispecific Antibodies for Aggressive Lymphomas2026